Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2025 | $15.00 | Buy | Lake Street |
| 7/22/2025 | $12.00 | Buy | Roth Capital |
| 9/26/2024 | $13.00 | Buy | B. Riley Securities |
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that the Centers for Medicare and Medicaid Services ("CMS") has added two of the electronic infusion pumps currently utilized by the Company within its Pain Management services business to the list of qualifying products for separate payment in conjunction with the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act. The NOPAIN Act mandates that CMS provide separate payment for qualified non-opioid treatments through December 31, 2027 when provided wit
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"),a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today Carrie Lachance, President and Chief Executive Officer and Barry Steele, Chief Financial Officer, will participate in the 16th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 18, 2025. The conference will be held at the Sheraton New York Times Square Hotel in New York City. Management is scheduled to host in-person one-on-one meetings held throughout the day. Investors interested in arranging one-on-one meetings should contact your Craig-Hal
Record Net Revenues of $36.5 million Representing 3% Growth from the Prior Year Net income of $2.3 million, up 25% Adjusted EBITDA (non-GAAP) of $8.3 million, up 6% Adjusted EBITDA (non-GAAP) margin expanded by 0.5% to 23% Year-to-Date Net Operating Cash Flow of $17.3 million, up 38% Stock Repurchases totaled $2.2 million during third quarter Reaffirms Full-Year 2025 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarte
Lake Street resumed coverage of InfuSystem with a rating of Buy and set a new price target of $15.00
Roth Capital initiated coverage of InfuSystem with a rating of Buy and set a new price target of $12.00
B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
4 - InfuSystem Holdings, Inc (0001337013) (Issuer)
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)
SCHEDULE 13G - InfuSystem Holdings, Inc (0001337013) (Subject)
8-K - InfuSystem Holdings, Inc (0001337013) (Filer)
The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and
InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has
Record Net Revenues of $36.5 million Representing 3% Growth from the Prior Year Net income of $2.3 million, up 25% Adjusted EBITDA (non-GAAP) of $8.3 million, up 6% Adjusted EBITDA (non-GAAP) margin expanded by 0.5% to 23% Year-to-Date Net Operating Cash Flow of $17.3 million, up 38% Stock Repurchases totaled $2.2 million during third quarter Reaffirms Full-Year 2025 Guidance InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarte
Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue third quarter 2025 financial results on Tuesday, November 4, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, November 4, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in t
Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)
SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)